During the past decade, CHU de Caen conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 5 clinical trials were completed, i.e. on average, 41.7% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 3 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU de Caen" #1 sponsor was "Centre Hospitalier Universitaire de Nīmes" with 3 trials, followed by "Galapagos NV" with 3 trials sponsored, "Pfizer" with 3 trials sponsored, "Actelion" with 2 trials sponsored and "Baxalta now part of Shire" with 2 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU de Caen" #1 collaborator was "Gilead Sciences" with 3 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Baxalta Innovations GmbH, now part of Shire" with 1 trials as a collaborator, "CRI-The Clinical Research Institute GmbH" with 1 trials as a collaborator and "Takeda Development Center Americas, Inc." with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "CHU de Caen" are "Crohn's Disease" (2 trials), "Pulmonary Arterial Hypertension" (2 trials), "Von Willebrand Disease" (2 trials), "Acute Kidney Injury" (1 trials) and "Acute Myeloid Leukemia" (1 trials). Many other conditions were trialed in "CHU de Caen" in a lesser frequency.

Most popular intervention types in "CHU de Caen" are "Drug" (13 trials), "Biological" (3 trials), "Device" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Filgotinib" (3 trials), "Antihemophilic Factor (Recombinant)" (2 trials), "von Willebrand factor (Recombinant)" (2 trials) and "10 days of intravenous placebo (isotonic saline)" (1 trials). Other intervention names were less common.

The vast majority of trials in "CHU de Caen" are 17 trials for "All" genders.

Currently, there are NaN active trials in "CHU de Caen". undefined are not yet recruiting, 5 are recruiting, 3 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 6 completed trials in CHU de Caen, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in CHU de Caen, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".